Market Overview:
The global anxiety disorders and depression therapeutic drug market is expected to register a CAGR of 6.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of anxiety disorders and depression, rising awareness about mental health issues, and technological advancements in the field of psychiatric drugs. However, stringent regulatory policies for drug approvals are likely to restrain the growth of this market during the forecast period. Based on type, SSRIs are expected to account for a major share of the global anxiety disorders and depression therapeutic drug market in 2018. This segment is projected to grow at a CAGR of 7% during the forecast period due to their high efficacy and safety profile as compared to other types of psychiatric drugs. SNRIs are also anticipated to witness significant growth during the forecast period owing their ability treat both anxiety disorders as well as depression simultaneously with fewer side effects than SSRIs or TCAs.
Product Definition:
Anxiety Disorders And Depression Therapeutic Drug is a drug that is used to treat anxiety disorders and depression. It is important because it can help people who are struggling with these conditions to feel better and function more effectively.
SSRIs:
SSRIs are selective serotonin receptor inhibitors. They work by increasing the amount of serotonin in the brain, which helps to improve both - depression and anxiety disorders. SSRIs are used as anti-depressants and anti-anxiety agents.
The global market for SSRIs is expected to grow at a significant rate during the forecast period due to growing prevalence of anxiety disorder globally, rising awareness about mental health among people especially in developing countries like India & China.
SNRIs:
Selective Serotonin Reuptake Inhibitors (SSRI) are a type of drug that increases the level of serotonin in the brain, which is associated with an increase in general wellbeing. They are used to treat various disorders including depression, anxiety, and post-traumatic stress disorder.
Application Insights:
Major depressive disorder (MDD) dominated the anxiety disorders and depression therapeutic drug market in terms of revenue in 2017. The high prevalence of MDD as well as other associated mental illnesses such as bipolar disorder, panic attacks, social phobia and OCD is anticipated to contribute significantly towards segment growth during the forecast period.
The others segment includes post-traumatic stress disorder (PTSD), social anxiety, specific phobias and other mental illnesses not covered under any of the abovementioned categories. High unmet needs for effective treatment for these conditions are expected to boost product demand in this segment over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to continue its dominance over the forecast period as well due to increasing cases of anxiety disorders and depression, growing awareness about mental health, and availability of effective treatment in this region. Moreover, presence of key pharmaceutical companies that are engaged in drug development for anxiety disorders is also one among the significant factors contributing toward regional growth.
Asia Pacific is anticipated to be the fastest-growing region during the forecast period owing to rising disposable income coupled with improving healthcare infrastructure especially in developing countries such as India and China. Growing medical tourism industry due to low cost of treatment & high quality services offered by various hospitals & clinics will also boost demand for anxiolytic & antidepressant drugs over next eight years.
Growth Factors:
- Increasing awareness about anxiety disorders and depression among people
- Growing number of research and development activities for the treatment of anxiety disorders and depression
- Rising demand for novel therapeutics for the treatment of anxiety disorders and depression
- increasing prevalence of stress-related disorders due to changing lifestyle patterns
- growing number of collaborations between pharmaceutical companies and research institutes to develop new therapies for anxiety disorders and depression
Scope Of The Report
Report Attributes
Report Details
Report Title
Anxiety Disorders And Depression Therapeutic Drug Market Research Report
By Type
SSRIs, SNRIs, TeCAs, TCAs, MAOIs, Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, Others
By Application
Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Phobia, Others
By Companies
Pfizer, Eli Lilly, AstraZeneca, Lundbeck, Merck & Co. Inc, Johnson & Johnson, Allergan, Sanofi, GSK, Bristol-Myers Squibb Company, Otsuka Pharmaceutical, Takeda, Shionogi, APOTEX, Kanghong Pharma, Zhejiang Huahai
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Anxiety Disorders And Depression Therapeutic Drug Market Report Segments:
The global Anxiety Disorders And Depression Therapeutic Drug market is segmented on the basis of:
Types
SSRIs, SNRIs, TeCAs, TCAs, MAOIs, Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Phobia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Eli Lilly
- AstraZeneca
- Lundbeck
- Merck & Co. Inc
- Johnson & Johnson
- Allergan
- Sanofi
- GSK
- Bristol-Myers Squibb Company
- Otsuka Pharmaceutical
- Takeda
- Shionogi
- APOTEX
- Kanghong Pharma
- Zhejiang Huahai
Highlights of The Anxiety Disorders And Depression Therapeutic Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- SSRIs
- SNRIs
- TeCAs
- TCAs
- MAOIs
- Atypical Antipsychotics
- Benzodiazepines
- Anticonvulsants
- Beta-Blockers
- Others
- By Application:
- Major Depressive Disorder (MDD)
- Obsessive-Compulsive Disorder (OCD)
- Phobia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anxiety Disorders And Depression Therapeutic Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anxiety disorders and depression are both mental illnesses that can be treated with medication.
Some of the key players operating in the anxiety disorders and depression therapeutic drug market are Pfizer, Eli Lilly, AstraZeneca, Lundbeck, Merck & Co. Inc, Johnson & Johnson, Allergan, Sanofi, GSK, Bristol-Myers Squibb Company, Otsuka Pharmaceutical, Takeda, Shionogi, APOTEX, Kanghong Pharma, Zhejiang Huahai.
The anxiety disorders and depression therapeutic drug market is expected to register a CAGR of 6.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anxiety Disorders And Depression Therapeutic Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anxiety Disorders And Depression Therapeutic Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anxiety Disorders And Depression Therapeutic Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anxiety Disorders And Depression Therapeutic Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anxiety Disorders And Depression Therapeutic Drug Market Size & Forecast, 2018-2028
4.5.1 Anxiety Disorders And Depression Therapeutic Drug Market Size and Y-o-Y Growth
4.5.2 Anxiety Disorders And Depression Therapeutic Drug Market Absolute $ Opportunity
Chapter 5 Global Anxiety Disorders And Depression Therapeutic Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Type
5.2.1 SSRIs
5.2.2 SNRIs
5.2.3 TeCAs
5.2.4 TCAs
5.2.5 MAOIs
5.2.6 Atypical Antipsychotics
5.2.7 Benzodiazepines
5.2.8 Anticonvulsants
5.2.9 Beta-Blockers
5.2.10 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anxiety Disorders And Depression Therapeutic Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Applications
6.2.1 Major Depressive Disorder (MDD)
6.2.2 Obsessive-Compulsive Disorder (OCD)
6.2.3 Phobia
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anxiety Disorders And Depression Therapeutic Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anxiety Disorders And Depression Therapeutic Drug Analysis and Forecast
9.1 Introduction
9.2 North America Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Type
9.6.1 SSRIs
9.6.2 SNRIs
9.6.3 TeCAs
9.6.4 TCAs
9.6.5 MAOIs
9.6.6 Atypical Antipsychotics
9.6.7 Benzodiazepines
9.6.8 Anticonvulsants
9.6.9 Beta-Blockers
9.6.10 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Applications
9.10.1 Major Depressive Disorder (MDD)
9.10.2 Obsessive-Compulsive Disorder (OCD)
9.10.3 Phobia
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anxiety Disorders And Depression Therapeutic Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Type
10.6.1 SSRIs
10.6.2 SNRIs
10.6.3 TeCAs
10.6.4 TCAs
10.6.5 MAOIs
10.6.6 Atypical Antipsychotics
10.6.7 Benzodiazepines
10.6.8 Anticonvulsants
10.6.9 Beta-Blockers
10.6.10 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Applications
10.10.1 Major Depressive Disorder (MDD)
10.10.2 Obsessive-Compulsive Disorder (OCD)
10.10.3 Phobia
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anxiety Disorders And Depression Therapeutic Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Type
11.6.1 SSRIs
11.6.2 SNRIs
11.6.3 TeCAs
11.6.4 TCAs
11.6.5 MAOIs
11.6.6 Atypical Antipsychotics
11.6.7 Benzodiazepines
11.6.8 Anticonvulsants
11.6.9 Beta-Blockers
11.6.10 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Applications
11.10.1 Major Depressive Disorder (MDD)
11.10.2 Obsessive-Compulsive Disorder (OCD)
11.10.3 Phobia
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anxiety Disorders And Depression Therapeutic Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Type
12.6.1 SSRIs
12.6.2 SNRIs
12.6.3 TeCAs
12.6.4 TCAs
12.6.5 MAOIs
12.6.6 Atypical Antipsychotics
12.6.7 Benzodiazepines
12.6.8 Anticonvulsants
12.6.9 Beta-Blockers
12.6.10 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Applications
12.10.1 Major Depressive Disorder (MDD)
12.10.2 Obsessive-Compulsive Disorder (OCD)
12.10.3 Phobia
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anxiety Disorders And Depression Therapeutic Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Type
13.6.1 SSRIs
13.6.2 SNRIs
13.6.3 TeCAs
13.6.4 TCAs
13.6.5 MAOIs
13.6.6 Atypical Antipsychotics
13.6.7 Benzodiazepines
13.6.8 Anticonvulsants
13.6.9 Beta-Blockers
13.6.10 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anxiety Disorders And Depression Therapeutic Drug Market Size Forecast by Applications
13.10.1 Major Depressive Disorder (MDD)
13.10.2 Obsessive-Compulsive Disorder (OCD)
13.10.3 Phobia
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anxiety Disorders And Depression Therapeutic Drug Market: Competitive Dashboard
14.2 Global Anxiety Disorders And Depression Therapeutic Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Eli Lilly
14.3.3 AstraZeneca
14.3.4 Lundbeck
14.3.5 Merck & Co. Inc
14.3.6 Johnson & Johnson
14.3.7 Allergan
14.3.8 Sanofi
14.3.9 GSK
14.3.10 Bristol-Myers Squibb Company
14.3.11 Otsuka Pharmaceutical
14.3.12 Takeda
14.3.13 Shionogi
14.3.14 APOTEX
14.3.15 Kanghong Pharma
14.3.16 Zhejiang Huahai
